Lipoprotein(a): an important consideration for DAPT therapy after PCI.
作者信息
Cui Kongyong, Dou Kefei
机构信息
Department of Cardiology, Cardiometabolic Medicine Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
State Key Laboratory of Cardiovascular Disease, Beijing, China.
出版信息
Cardiol J. 2024;31(2):365-366. doi: 10.5603/cj.98494.
Abstract
摘要
相似文献
1
Lipoprotein(a): an important consideration for DAPT therapy after PCI.脂蛋白(a)：PCI术后双联抗血小板治疗的重要考量因素
Cardiol J. 2024;31(2):365-366. doi: 10.5603/cj.98494.
2
Incidence, Patterns, and Impact of Dual Antiplatelet Therapy Cessation Among Patients With and Without Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention: Results From the PARIS Registry (Patterns of Non-Adherence to Anti-Platelet Regimens in Stented Patients).接受经皮冠状动脉介入治疗的慢性肾脏病患者和非慢性肾脏病患者中断双联抗血小板治疗的发生率、模式和影响：PARIS 登记研究（支架置入患者抗血小板治疗方案不依从模式）的结果。
Circ Cardiovasc Interv. 2018 Mar;11(3):e006144. doi: 10.1161/CIRCINTERVENTIONS.117.006144.
3
DAPT Shortening After Complex PCI: Examining the Fine Print.复杂经皮冠状动脉介入治疗后双联抗血小板治疗疗程的缩短：研读细则
J Am Coll Cardiol. 2023 Jun 6;81(22):e191. doi: 10.1016/j.jacc.2023.02.053.
4
Reply: DAPT Shortening After Complex PCI: Examining the Fine Print.
J Am Coll Cardiol. 2023 Jun 6;81(22):e193. doi: 10.1016/j.jacc.2023.03.425.
5
Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials.经皮冠状动脉介入治疗（PCI）使用药物洗脱支架后抗血小板治疗方案的安全性和有效性：一项随机对照试验的网络荟萃分析。
Prog Cardiovasc Dis. 2020 May-Jun;63(3):243-248. doi: 10.1016/j.pcad.2020.03.018. Epub 2020 Apr 3.
6
Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial.新型血小板聚集功能检测指导下的稳定型冠状动脉疾病行经皮冠状动脉介入治疗患者的个体化抗血小板治疗：一项随机对照临床试验。
Eur Heart J Cardiovasc Pharmacother. 2020 Jul 1;6(4):211-221. doi: 10.1093/ehjcvp/pvz059.
7
Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary Intervention.基线贫血对经皮冠状动脉介入治疗后双联抗血小板治疗停药和不良事件风险的影响。
Circ Cardiovasc Interv. 2019 Apr;12(4):e007133. doi: 10.1161/CIRCINTERVENTIONS.118.007133.
8
Risk/Benefit Tradeoff of Prolonging Dual Antiplatelet Therapy More Than 12 Months in TWILIGHT-Like High-Risk Patients After Complex Percutaneous Coronary Intervention.TWILIGHT 样高危经皮冠状动脉介入治疗后双联抗血小板治疗延长 12 个月以上的风险/获益权衡。
Am J Cardiol. 2020 Oct 15;133:61-70. doi: 10.1016/j.amjcard.2020.07.033. Epub 2020 Jul 24.
9
DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI.DAPT 评分与 PCI 后第二年替格瑞洛单药治疗的影响。
JACC Cardiovasc Interv. 2020 Mar 9;13(5):634-646. doi: 10.1016/j.jcin.2019.12.018.
10
Dual antiplatelet therapy in patients with a long coronary artery lesion over 30 mm: Determinants and impact on prognosis.30毫米以上长冠状动脉病变患者的双联抗血小板治疗：决定因素及对预后的影响
Arch Cardiovasc Dis. 2015 Apr;108(4):235-43. doi: 10.1016/j.acvd.2014.11.004. Epub 2015 Feb 11.
本文引用的文献
1
Prolonged dual antiplatelet therapy in invasively treated acute coronary syndrome patients with different lipoprotein(a) concentrations.不同脂蛋白（a）浓度的接受侵入性治疗的急性冠脉综合征患者的延长双联抗血小板治疗
Cardiol J. 2024;31(1):32-44. doi: 10.5603/cj.93062. Epub 2023 Oct 19.
2
Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial.急性冠状动脉综合征患者使用低剂量替格瑞洛联合或不联合乙酰水杨酸：ELECTRA-SIRIO 2试验的原理与设计
Cardiol J. 2022;29(1):148-153. doi: 10.5603/CJ.a2021.0118. Epub 2021 Oct 8.
3
Association of lipoprotein(a) with platelet aggregation and thrombogenicity in patients undergoing percutaneous coronary intervention.脂蛋白(a)与经皮冠状动脉介入治疗患者血小板聚集和血栓形成的相关性。
Platelets. 2021 Jul 4;32(5):684-689. doi: 10.1080/09537104.2020.1802412. Epub 2020 Aug 13.
4
Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype.血小板CD36将高脂血症、氧化应激与血栓前表型联系起来。
Nat Med. 2007 Sep;13(9):1086-95. doi: 10.1038/nm1626. Epub 2007 Aug 26.
5
Arginyl-glycyl-aspartyl (RGD) epitope of human apolipoprotein (a) inhibits platelet aggregation by antagonizing the IIb subunit of the fibrinogen (GPIIb/IIIa) receptor.人载脂蛋白(a)的精氨酰-甘氨酰-天冬氨酰（RGD）表位通过拮抗纤维蛋白原（GPIIb/IIIa）受体的IIb亚基来抑制血小板聚集。
Thromb Res. 2007;119(5):601-7. doi: 10.1016/j.thromres.2006.04.013. Epub 2006 Jul 21.
6
Effect of lipoprotein (a) on platelet activation induced by platelet-activating factor: role of apolipoprotein (a) and endogenous PAF-acetylhydrolase.脂蛋白(a)对血小板活化因子诱导的血小板活化的影响：载脂蛋白(a)和内源性血小板活化因子乙酰水解酶的作用
Cardiovasc Res. 2004 Jul 1;63(1):130-8. doi: 10.1016/j.cardiores.2004.03.005.
7
Apolipoprotein(a) enhances platelet responses to the thrombin receptor-activating peptide SFLLRN.
Arterioscler Thromb Vasc Biol. 1998 Sep;18(9):1393-9. doi: 10.1161/01.atv.18.9.1393.
Zotero 插件